Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDMX can interact with MDM2, leading to enhanced MDM2 stabilization and p53 degradation, but the full importance of the MDMX-MDM2 interaction is unclear (Marine et al., 2006; Wade et al., 2010).”
From p53 at a glance (2010) · cites this paper as Marine et al., 2006
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Self-citationmdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Self-citationOxygen sensitivity severely limits the replicative lifespan of murine fibroblasts
Parrinello, S., Samper, E., Krtolica, A., Goldstein, J., Melov, S., & Campisi, J. (2003) · Nature Cell Biology · doi:10.1038/ncb1024 · Cited by 1,116
Research works printed but not linked: 3
- Finch RA et al. (2002); 62: 3221–3225.
- Xiang S et al. (2006) Proc. Natl. Acad. Sci. USA. Feb 21 [Epub ahead of print].
- Francoz S et al. (2006) Proc. Natl. Acad. Sci. Feb 21 [Epub ahead of print].
Cited by
Items 201–300 of 365
Regulating the genome surveillance system: miRNAs and the p53 super family
Bailey, S. G., Sánchez-Elsner, T., Stephanou, A., Cragg, M. S., & Townsend, P. A. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0456-1 · Cited by 22
“In simple terms, once bound, Mdm2 inhibits p53 activity by blocking transcription and targeting it for degradation [26, 27].”
BackgroundAch, T., Schwarz‐Furlan, S., Ach, S., Agaimy, A., Gerken, M., Rohrmeier, C., Zenk, J., Iro, H., Brockhoff, G., & Ettl, T. (2015) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12394 · Cited by 23
“In this context, MDM4 is able to stabilize the MDM2-p53 complex (53).”
BackgroundSingh, R. K., Tapia-Santos, A. S., Bebee, T. W., & Chandler, D. S. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.07.017 · Cited by 22
Costa, A. F., Gomes, S. Z., Lorenzon, A. R., Martucci, M. F., Faria, M. F. D. O., Júnior, D. D. S. P., de Oliveira, S. F., Ietta, F., Paulesu, L. R., & Bevilacqua, E. M. A. F. (2016) · Placenta · doi:10.1016/j.placenta.2016.03.001 · Cited by 22
“Mdm2 binds specifically to p53, blocking its activities and the expression of p53-responsive target genes [37], and it also activates E3 ubiquitin ligase that targets proteasomal degradation of p53 [38].”
Guardian of corpulence: a hypothesis on p53 signaling in the fat cell
Bazuine, M., Stenkula, K. G., Cam, M., Arroyo, M., & Cushman, S. W. (2009) · Clinical Lipidology · doi:10.2217/clp.09.2 · Cited by 22
Protecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20
“Mdmx can, paradoxically, facilitate Mdm2mediated p53 ubiquitination, but it is also reported to stabilize p53; this is postulated to be due to the relative levels of Mdmx and Mdm2 in the cell.(16,17) Ultimately, posttranslational modifications of Mdm2, Mdmx, and p53 are thought to allow p53 activation following DNA da…”
BackgroundHepburn, L. A., McHugh, A. T., Fernandes, K., Boag, G., Proby, C. M., Leigh, I. M., & Saville, M. K. (2018) · Oncotarget · doi:10.18632/oncotarget.25196 · Cited by 21
“Pladienolide B and SF3B1 knockdown reduced MDMX and MDM2 protein expression in cSCC lines, indicating that these effects can occur independently of wild-type p53 (Supplementary Figures 4 and 5).”
BackgroundInfluentialThe Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma
Hsieh, C., & Shen, C. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0622-9 · Cited by 20
Ubiquitin Ligases in Cancer: Ushers for Degradation
Newton, K., & Vucic, D. (2007) · Cancer Investigation · doi:10.1080/07357900701508041 · Cited by 21
“Genetic evidence indicates that both Mdm4 (also called MdmX) and Mdm2 keep p53 transcriptional activity in check (174).”
BackgroundLiu, L., Fan, L., Cheng, F., Zou, Z., Yang, S., Zhang, L., Li, J., & Xu, W. (2012) · Cancer Science · doi:10.1111/cas.12008 · Cited by 23
Notch and the p53 Clan of Transcription Factors
Roemer, K. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0899-4_17 · Cited by 22
Eskandari, M. R., Shi, Y., Liu, J., Albanese, J. M., Goel, S., Verma, A. K., & Wang, Y. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1817441 · Cited by 19
Han, X., Medeiros, L. J., Zhang, Y. H., You, M. J., Andreeff, M., Konopleva, M. Y., & Bueso-Ramos, C. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.03.012 · Cited by 20
Evolution of Conformational Disorder & Diversity of the P53 Interactome
Huart, A.-S., & Hupp, T. R. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.5 · Cited by 24
“P53 transcriptionally activates the mdm2 gene and because MDM2 inhibits p53 activity, this forms a negative feedback loop that regulates p53 function [27].”
BackgroundWalter, R. F. H., Vollbrecht, C., Werner, R., Mairinger, T., Schmeller, J., Flom, E., Wohlschlaeger, J., Barbetakis, N. G., Paliouras, D., Chatzinikolaou, F. G., et al. (2016) · Journal of Cancer · doi:10.7150/jca.16390 · Cited by 20
“P14/ARF may control TP53 transcription, represses TP53 degradation that is not MDM2-mediated and stimulates TP53 activity [84].”
BackgroundInfluentialFan, Y., Ma, K., Jing, J., Wang, C., Hu, Y., Shi, Y., Li, E., & Geng, Q. (2019) · Journal of Cancer · doi:10.7150/jca.32765 · Cited by 20
Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection
Yang, H., Zheng, Z., Zhao, L., Li, Q., & Liao, D. (2012) · Cell Cycle · doi:10.4161/cc.11.3.19052 · Cited by 19
Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck
Yu, H., Wang, L., Liu, Z., Wei, S., Li, G., Sturgis, E. M., & Wei, Q. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834632e4 · Cited by 19
“Recent data have shown that MDM4 stabilizes the p53-MDM2 complex and enhances the function of the E3 ubiquitin ligase of MDM2, accelerating degradation of p53 [12].”
BackgroundNon-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age
Fontebasso, A. M., Shirinian, M., Khuong-Quang, D.-A., Béchet, D., Gayden, T., Kool, M., Jay, N. D., Jacob, K., Gerges, N., Hutter, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5571 · Cited by 26
“MDM2 targets p53 for degradation and its amplification/overexpression mimics TP53 loss[50, 51].”
BackgroundMDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability
Mancini, F., Teveroni, E., Conza, G. D., Monteleone, V., Arisi, I., Pellegrino, M., Buttarelli, M., Pieroni, L., D’Onofrio, M., Urbani, A., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0626-7 · Cited by 20
“Under mild cytostatic DNA damage, the protein is actively degraded and this allows p53 to execute its growth arrest response [2].”
Induction of ASAP (MAP9) contributes to p53 stabilization in response to DNA damage
Basbous, J., Knani, D., Bonneaud, N., Giorgi, D., Brondello, J., & Rouquier, S. (2012) · Cell Cycle · doi:10.4161/cc.20858 · Cited by 19
Indispensable role of Mdm2/p53 interaction during the embryonic and postnatal inner ear development
Laos, M., Sulg, M., Herranen, A., Anttonen, T., & Pirvola, U. (2017) · Scientific Reports · doi:10.1038/srep42216 · Cited by 18
Liu, S., Xu, T., Wu, X., Lin, Y., Bao, D., Yang, D., Ma, T., Dang, Y., Jia, P., Xian, J., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.07.007 · Cited by 17
Pissaloux, D., Loarer, F. L., Decouvelaere, A., Paindavoine, S., Houlier, A., Vernay, L., Bland, V., Coindre, J., Blay, J., & Ranchère‐Vince, D. (2017) · Histopathology · doi:10.1111/his.13331 · Cited by 17
“MDM2 and MDM4 have synergistic functions in TP53 regulation; both can interact directly with TP53 and inhibit its activity either by promoting its degradation or repressing its transcriptional activation domain.(4) MDM4 is a bona fide oncogene amplified in a subset of colorectal carcinomas, glioblastomas and retinobla…”
Backgroundp53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy
Rodriguez-Ramirez, C., & Nor, J. E. (2018) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018027353 · Cited by 17
Regulation of MDM4 (MDMX) function by p76MDM2: a new facet in the control of p53 activity
Giglio, S., Mancini, F., Pellegrino, M., Conza, G. D., Puxeddu, E., Sacchi, A., Pontecorvi, A., & Moretti, F. (2010) · Oncogene · doi:10.1038/onc.2010.324 · Cited by 17
“Under normal growth conditions, p53 activity is tightly controlled by MDM family members, MDM2 and MDM4, and their derivative forms (Marine et al., 2006; Toledo and Wahl 2007; Mancini et al., 2009a).”
BackgroundInfluentialFregni, M., Ciribilli, Y., & Zawacka‐Pankau, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137213 · Cited by 18
Walter, R. F. H., Vollbrecht, C., Werner, R., Wohlschlaeger, J., Christoph, D. C., Schmid, K. W., & Mairinger, F. D. (2016) · Oncotarget · doi:10.18632/oncotarget.7666 · Cited by 19
Zawacka‐Pankau, J. (2020) · Cancers · doi:10.3390/cancers12092717 · Cited by 17
“The affinities of MDM2 and MDMX to p73 are of the same order as to p53, Kd (µM) = 1.4 and Kd (µM) = 0.22, respectively [84].”
BackgroundInfluentialFan, C., & Wang, X. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1288327 · Cited by 17
Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells
Samudio, I. J., Duvvuri, S. R., Clise-Dwyer, K., Watt, J. C., Mak, D. H. F., Kantarjian, H. M., Yang, D., Ruvolo, V. R., & Borthakur, G. M. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003731325 · Cited by 17
Kosztyu, P., Slaninová, I., Valčíková, B., Verlande, A., Müller, P., Palecek, J. J., & Uldrijan, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00390 · Cited by 16
“…which work together to control the levels and activity of the tumor suppressor p53 during embryonic development and in unstressed healthy cells (Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001; Migliorini et al., 2002; Marine et al., 2006; Ringshausen et al., 2006).”
BackgroundCorrelation between Oncogenic Mutations and Parameter Sensitivity of the Apoptosis Pathway Model
Chen, J., Yue, H., & Ouyang, Q. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003451 · Cited by 16
“Nuclear p53 induces mdm2 transcription, while MDM2 antagonizes p53 by promoting multistep ubiquitination and proteasome-dependent degradation of p53 [13,14].”
BackgroundMoradi, M., Salehi, Z., Aminian, K., & Yazdanbod, A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.17.7413 · Cited by 15
“Several epidemiological studies have evaluated the connection of p53 R72P, MDM2 SNP309 and risk of different types of cancer (Marine et al., 2006; Sadeghi et al., 2013; Song et al., 2013).”
BackgroundMDM2/MDMX: Master negative regulators for p53 and RB
Hu, L., Zhang, H., Bergholz, J. S., Sun, S., & Xiao, Z. J. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1106635 · Cited by 16
“MDM2 and MDMX are predominantly found as heterodimers, which is thought to enhance E2 protein recruitment and stabilize the ternary complex containing tumor protein p53 (best known as p53).(6) In our study, we found that MDMX enhances the ability of MDM2 to bind to and promote RB degradation.”
BackgroundMatijašević, Z., Krzywicka-Racka, A., Sluder, G., Gallant, J., & Jones, S. N. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.62 · Cited by 14
Lucà, R., Assenza, M. R., Maiullari, F., Pieroni, L., Maiullari, S., Federici, G., Marini, F., Rizzi, R., Urbani, A., Soddu, S., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03828-z · Cited by 15
p53-targeted cancer pharmacotherapy: move towards small molecule compounds
Kim, S.-H., & Dass, C. R. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01248.x · Cited by 15
“This physical interaction prevents p53 from interacting with its transcription factors.([22]) Mdm2 also induces p53 degradation by the ubiquitylation function of the E3 ubiquitin ligase.”
BackgroundHuart, A.-S., SAXTY, B. A., Merritt, A. T., Nekulová, M., Lewis, S., Huang, Y., Vojtěšek, B., Kettleborough, C. A., & Hupp, T. R. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.046 · Cited by 15
Bahk, Y. Y., Lee, J., Cho, I.-H., & Lee, H. (2010) · Journal of Proteome Research · doi:10.1021/pr100552y · Cited by 15
Walter, R. F. H., Werner, R., Wessolly, M., Mairinger, E., Borchert, S., Schmeller, J., Kollmeier, J., Mairinger, T., Hager, T., Bánkfalvi, Á., et al. (2018) · Journal of Oncology · doi:10.1155/2018/1986982 · Cited by 14
Heijkants, R. C., Teunisse, A. F. A. S., de Jong, D., Glinkina, K., Mei, H., Kiełbasa, S. M., Szuhai, K., & Jochemsen, A. G. (2022) · Cancers · doi:10.3390/cancers14184482 · Cited by 14
Cannistraro, S., Moscetti, I., Teveroni, E., Moretti, F., & Bizzarri, A. R. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s114705 · Cited by 13
“p53 is regulated by a complex network within which Murine double minute 2 (MDM2) and 4 (MDM4 or MDMX) are the main negative regulators.(4) Both MDM2 and MDM4 are able to inhibit the transcriptional activity of p53 by physically binding with its N-terminal transactivation domain.”
BackgroundMaternal SNPs in the p53 Pathway: Risk Factors for Trisomy 21?
Boquett, J. A., Brandalize, A. P. C., Fraga, L. R., & Schüler‐Faccini, L. (2013) · Disease Markers · doi:10.1155/2013/302920 · Cited by 17
MDM4 overexpression contributes to synoviocyte proliferation in patients with rheumatoid arthritis
Xu, N., Wang, Y., Li, D., Chen, G., Sun, R., Zhu, R., Sun, S., Liu, H., Yang, G., & Dong, T. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.069 · Cited by 14
MDM2/MDMX inhibitor peptide: WO2008106507
Macchiarulo, A., & Pellicciari, R. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902755137 · Cited by 13
“Conversely, the interaction of MDMX with the trans-activation function of p53 does not target the tumor suppressor protein for the degradation, but inactivates its transcriptional activity [3,4].”
BackgroundDementia and Cancer: A Review of the Literature and Current Practice
Solomons, L. C., Solomons, J., & Gosney, M. (2013) · Aging Health · doi:10.2217/ahe.13.27 · Cited by 12
Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids
Chee, S. M. Q., Wongsantichon, J., Siau, J. W., Thean, D., Ferrer, F. J., Robinson, R. C., Lane, D. P., Brown, C. J., & Ghadessy, F. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189379 · Cited by 12
Interleukin 6 Knockout Inhibits Aging-Related Accumulation of p53 in the Mouse Myocardium
Bonda, T. A., Dziemidowicz, M., Cieślińska, M., Tarasiuk, E., Wawrusiewicz‐Kurylonek, N., Bialuk, I., Winnicka, M. M., & Kamiński, K. A. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly105 · Cited by 11
Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC
Pellegrino, R., Thavamani, A., Calvisi, D. F., Budczies, J., Neumann, A., Geffers, R., Kroemer, J., Greule, D., Schirmacher, P., Nordheim, A., et al. (2021) · Cancers · doi:10.3390/cancers13020199 · Cited by 12
“P53 is regulated by a network of interacting factors, most prominently by genes of the mouse double minute (MDM) family [11].”
BackgroundNovel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
Grinkevich, V. V., Vema, A., Fawkner, K., Issaeva, N., Andreotti, V., Dickinson, E. R., Hedström, E., Spinnler, C., Inga, A., Larsson, L., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.823195 · Cited by 12
“This is due to structural difference in the p53 binding pocket (Marine et al., 2006; Toledo and Wahl, 2007; Jiang and Zawacka-Pankau, 2020).”
BackgroundMarine, J. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.026 · Cited by 12
“Mouse genetic experiments have highlighted nonoverlapping and synergistic p53inhibitory activities of Mdm2 andMdmx throughout embryonicdevelopment (reviewed in Marine et al., 2006).”
BackgroundSelf-citationMutation analysis of the MDM4gene in German breast cancer patients
Reincke, S., Govbakh, L., Wilhelm, B., Jin, H., Bogdanova, N. V., Bremer, M., Karstens, J. H., & Dörk, T. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-52 · Cited by 11
Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens
Siau, J. W., Coffill, C. R., Zhang, W. V., Tan, Y. S., Hundt, J., Lane, D., Verma, C., & Ghadessy, F. (2016) · Scientific Reports · doi:10.1038/srep33972 · Cited by 13
Walter, R. F. H., Vollbrecht, C., Christoph, D. C., Werner, R., Schmeller, J., Flom, E., Trakada, G., Rapti, A., Adamidis, V., Hohenforst‐Schmidt, W., et al. (2016) · Journal of Cancer · doi:10.7150/jca.16925 · Cited by 11
“Tumors infiltrating lymph nodes present with higher frequency of TP53 variants (p=0.0007), as well as ERBB2 variants (p=0.0051) or BRAF mutations (p=0.0468).”
InfluentialZhang, L., Zhang, J., Xuan, X., Wu, D., Yu, J., Wang, P., Yang, X., Zhang, J., Gan, W., He, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112833 · Cited by 12
Khanlou, Z. M., Pouladi, N., Feizi, M. A. H., & Pedram, N. (2017) · PubMed Central · doi:10.22034/apjcp.2017.18.4.1133 · Cited by 10
“Genetic amplification of the MDM2 or MDM4 genes can result in the aberrant protein expression and suppression of the p53 response over the course of tumor development and progression (Marine et al., 2006; Wade et al., 2010).”
BackgroundThe alternative translated MDMXp60isoform regulates MDM2 activity
Tournillon, A.-S., López, I., Malbert-Colas, L., Naski, N., Olivares‐Illana, V., & Fåhræus, R. (2015) · Cell Cycle · doi:10.4161/15384101.2014.977081 · Cited by 10
“MDM2 and its homolog MDMX are both essential but non-redundant regulators of p53 activity during development but MDMX does not exhibit E3 ligase activity toward p53.(11,22) Instead, it has been proposed that the main activity of full length MDMX toward p53 is mediated via an interference with p53’s transactivation act…”
Backgroundp53 Regulation Goes Live--Mdm2 and MdmX Co-Star: Lessons Learned from Mouse Modeling
Tollini, L. A., & Zhang, Y. (2012) · Genes & Cancer · doi:10.1177/1947601912454732 · Cited by 11
A common pathway to cancer: Oncogenic mutations abolish p53 oscillations
Xiong, L., & Garfinkel, A. (2022) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2022.06.002 · Cited by 10
Mutational analysis reveals a dual role of Mdm2 acidic domain in the regulation of p53 stability
Doleželová, P., Cetkovská, K., Vousden, K. H., & Uldrijan, S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.05.034 · Cited by 12
Li, X., Yang, X., Chang, L., Wang, Z., Wang, T., Zhang, Z., Bai, J., Liang, R., Niu, Q. L., & Zhang, H. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.04.025 · Cited by 9
Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo
Klimovich, B., Stiewe, T., & Timofeev, O. N. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1693748 · Cited by 9
“In addition, Mdm2 and Mdm4 can inhibit transcriptional activity of p53 via binding to its N-terminal transactivation domain [20].”
BackgroundPulzová, L., Roška, J., Kalman, M., Kliment, J., Slávik, P., Smolková, B., Goffa, E., Jurkovičová, D., KULCSAR, L., Lešková, K., et al. (2021) · Cancers · doi:10.3390/cancers13215573 · Cited by 9
“The function of p53 in cancer is often compromised by overexpression of MDM2 or MDMX, with both homologs being negative regulators of its intracellular levels [42].”
BackgroundSun, L., Gao, X., Wang, M., Zhang, Y., Sun, R., Chen, Y., Bai, Y., Li, Y., Luo, L., Ding, C., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217854 · Cited by 9
Zhang, Y., Sturgis, E. M., Wei, P., Liu, H., Wang, Z., Ma, Y., Liu, C., Gu, K. J., Wei, Q., & Li, G. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23116 · Cited by 9
Vivenza, D., Monteverde, M., Lattanzio, L., Tonissi, F., Astesana, V., Denaro, N., Comino, A., Russi, E. G., Nigro, C. L., & Merlano, M. C. (2016) · The International Journal of Biological Markers · doi:10.5301/jbm.5000192 · Cited by 7
“Not surprisingly, both MDM2 and MDMX are overexpressed in different neoplasms (30).”
BackgroundThe role of ubiquitination in spinal and bulbar muscular atrophy
Sengupta, M., Pluciennik, A., & Merry, D. E. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1020143 · Cited by 7
“A partial knockdown of the DUB USP7 in a cellular model of SBMA rescued AR-associated aggregation and cell death; yet, a near-complete knockdown failed to do so (Pluciennik et al., 2021), likely due to confounding effects on other proteins that impact AR levels.”
BackgroundInfluentialLu, Z., Sturgis, E. M., Zhu, L., Zhang, H., Tao, Y., Wei, P., Wei, Q., & Li, G. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22760 · Cited by 7
“Moreover, MDM4 plays an essential role in MDM2-MDM4–p53 regulatory circuit by enhancing the function of the E3 ubiquitin ligase of MDM2 and promoting degradation of p53.(20) Amplification”
BackgroundTargeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6
“Although MDM4 lacks intrinsic E3 ligase activity, it forms heterodimers with MDM2, which stabilizes MDM2 and enhances its E3 ligase function toward p53 [91].”
Lama, R., Galster, S. L., Xu, C., Davison, L. W., Chemler, S. R., & Wang, X. (2022) · Molecules · doi:10.3390/molecules27227665 · Cited by 6
“The N-terminus of both MDM2 and MDM4 binds to the p53 transactivation domain and inhibits the p53-dependent transcriptional transactivation of the downstream genes, while the C-terminal RING domain of MDM2 can bind to E2 ubiquitin-conjugating enzymes for p53 ubiquitination and to the RING domain of MDM4 to form hetero…”
Backgroundp53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis
Tashakori, M., Zhang, Y., Xiong, S., You, M. J., & Lozano, G. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0346 · Cited by 6
Self-citationChemical induced alterations in p53 signaling
Högberg, J., Silins, I., & Stenius, U. (2009) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-7643-8336-7_7 · Cited by 6
Ubiquitin Family Members in the Regulation of the Tumor Suppressor p53
Xirodimas, D. P., & Scheffner, M. (2010) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4419-6676-6_10 · Cited by 5
Akmal, M. F., & Wong, M. W. (2025) · Molecules · doi:10.3390/molecules30142992 · Cited by 4
De la mesure en toute chose : dérégulation de p53, cancer et syndromes télomériques
Jaber, S., Simeonova, I., & Toledo, F. (2013) · médecine/sciences · doi:10.1051/medsci/20132912003 · Cited by 4
Self-citationStieg, D. C., Casey, K., Karisetty, B. C., Leu, J. I.-J., Larkin, F., Vogel, P., Madžo, J., & Murphy, M. E. (2024) · Molecular and Cellular Biology · doi:10.1080/10985549.2024.2421885 · Cited by 4
“26 However, we previously showed an increased steady-state level of G334R in heterozygous LCLs, but not in LCLs containing DNA-binding domain mutations in TP53; 21 moreover, these heterozygous G334R LCLs showed normal transactivation of MDM2, compared to WT LCLs. 21 Therefore, we tested the ability…”
Cell motility and breast cancer metastasis
Bracke, M., Maeseneer, D. J. D., Marck, V. V., Derycke, L., Vanhoecke, B. W. A., Wever, O. D., & Depypere, H. T. (2007) · Cancer metastasis · doi:10.1007/978-1-4020-5867-7_4 · Cited by 4
Evaluation of DNA Methylation of MAP9 Gene in Breast Cancer as Epigenetic Biomarker
Kavousi, F. (2016) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.s8-015 · Cited by 3
“In response to DNA damage, N-terminal domain of MAP9 interacts with p53 which it helps to stabilize p53, as well as increment in p53dependent transcription [21].”
BackgroundLong-Read MDM4 Sequencing Reveals Aberrant Isoform Landscape in Metastatic Melanomas
Patrick, N., & Markey, M. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179415 · Cited by 2
“15,16].”
BackgroundRaab, M., Gasimli, K., Győrffy, B., Peña‐Llopis, S., Becker, S., Sanhaji, M., & Strebhardt, K. (2025) · Cancers · doi:10.3390/cancers17121910 · Cited by 2
“The feedback loop p53-MDM2 may also trigger MDM2 autoubiquitination and degradation, reducing its levels [59].”
Kwon, Y., Yoon, H., Han, J., Park, J. W., & Jang, K. L. (2026) · FEBS Letters · doi:10.1002/1873-3468.70275 · Cited by 2
“MDM2 is a representative negative regulator of p53, which binds to the N-terminal domain of p53 and promotes its ubiquitination and degradation [3,5,29].”
Kim, Y., Shin, S. Y., Jung, S., & Chung, Y. (2020) · BMC Medical Genetics · doi:10.1186/s12881-020-01137-4 · Cited by 2
Ntwasa, M. M. (2024) · Cells · doi:10.3390/cells13131124 · Cited by 2
“Notably, heterozygosity does not rescue the Mdmd2 − / − phenotype, but a hypomorphic allele of p53 lacking the proline-rich domain does not rescue an Hdm2 null phenotype in contrast to Hdm4 [18].”
BackgroundThe p53-Mdm2 Loop: A Critical Juncture of Stress Response
Levav-Cohen, Y., Goldberg, Z., Alsheich-Bartok, O., Zuckerman, V., Haupt, S., & Haupt, Y. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_5 · Cited by 3
Cooperation between MDM2 and MDMX in the Regulation of p53
Blaydes, J. P. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_6 · Cited by 3
Inferring Contagion in Regulatory Networks
Fujita, A., Sato, J. R., Demasi, M. A. A., Yamaguchi, R., Shimamura, T., Ferreira, C. E., Sogayar, M. C., & Miyano, S. (2010) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2010.40 · Cited by 2
Xu, Z., & Wei, B. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03081.x · Cited by 2
P53 and microRNAs in chronic lymphocytic leukemia
Bloehdorn, J., Langer, C., Döhner, H., Zenz, T., & Stilgenbauer, S. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.e8 · Cited by 2
Jaber, S., Eldawra, E., Rakotopare, J., Simeonova, I., Lejour, V., Gabriel, M., Cañeque, T., Volochtchouk, V., Licaj, M., Fajac, A., et al. (2024) · eLife · doi:10.7554/elife.102434 · Cited by 3
“This provides a powerful assay for analyzing the functionality of p53 mutant alleles ( Bardot et al., 2015 ; Iwakuma et al., 2004 ; Marine et al., 2006 ; Toledo et al., 2006 ).”
Self-citationDeveloping Genetically Engineered Mouse Models to Study Tumor Suppression
Xiong, S., Parker‐Thornburg, J., & Lozano, G. (2012) · Current Protocols in Mouse Biology · doi:10.1002/9780470942390.mo110159 · Cited by 2
“Mdm2 is an E3 ubiquitin ligase that complexes with Mdm4 to target p53 for degradation (Marine et al., 2006).”
BackgroundSelf-citationJaber, S., Eldawra, E., Rakotopare, J., Simeonova, I., Lejour, V., Gabriel, M., Cañeque, T., Volochtchouk, V., Licaj, M., Fajac, A., et al. (2025) · eLife · doi:10.7554/elife.102434.3 · Cited by 2
Self-citationSMN deficiency-induced alternative splicing dysregulation in cardiac defects
Jiang, L., Wang, X., Cui, Y., Zhou, D., Yang, Z., Cheng, H., & Shanshan, M. A. O. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124361 · Cited by 1
Lu, X., Zang, K., Diao, C., Dong, C., & Ren, J. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c08142 · Cited by 1
ATM induces radioresistance of non-small cell lung cancer A549 cells by downregulation of MDMX
Xing, R., Chen, J. J., Chen, M. Y., Lian, J., Li, L. F., Zhou, X., Liu, R., Xie, Y., Huang, W., Zhao, H., et al. (2020) · Internatuinal Journal of Radiation Research · doi:10.52547/ijrr.18.4.835 · Cited by 1
“There were reports indicated that both MDM2 and MDMX are required to inhibit p53 activity in the same cell type, which confirmed the notion that MDM2 can not compensate for MDMX loss(17).”
Backgroundp53: Point Mutations, SNPs and Cancer
Fang, M., Simeonova, I., & Toledo, F. (2012) · InTech eBooks · doi:10.5772/33715 · Cited by 2
“ubiquitin ligase that can lead to the degradation of p53 by the proteasome (Brooks and Gu, 2006), whereas Mdm4 inhibits the activity of p53 mainly by occluding the p53 transactivation domain (Marine et al., 2006).”
BackgroundSelf-citationP53 and microRNAs in chronic lymphocytic leukemia
Bloehdorn, J., Langer, C., Döhner, H., Zenz, T., & Stilgenbauer, S. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.2414 · Cited by 2
“minute 4 (MDM4) facilitates a shift towards a p53 dominance.(30,31) Induction or repression of”
BackgroundGeorge, M. D., Verhoeven, D. E., Sankaran, S., Dang, A. T., & Dandekar, S. (2008) · Journal of Medical Primatology · doi:10.1111/j.1600-0684.2008.00322.x · Cited by 1
Manfredi, J. J. (2009) · Genes & Development · doi:10.1101/gad.1778309 · Cited by 1
“Both of these proteins have been shown to be overexpressed in human cancer and to have oncogenic activity in model systems (Marine et al. 2006).”
Background
Metadata
- Authors
- Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Salk Institute for Biological Studies (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Marine, J-C
- Venue
- Cell Death & Differentiation
- Published
- 2006-03-17
- Volume
- 13
- Issue
- 6
- Pages
- 927-934
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2126832141
- Cited by
- 352
- References
- 27
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 8 · 2021: 9 · 2020: 16 · 2019: 12 · 2018: 16 · 2017: 16 · 2016: 14 · 2015: 14 · 2014: 26 · 2013: 17 · 2012: 27
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, MDM2, MDM4, p53 regulation, tumor suppressor, DNA damage response, oxidative stress, oncogene activation, mitotic stress, cell cycle arrest, apoptosis, p21, pro-apoptotic genes, p53 target genes
- MeSH terms
- Animals, Antineoplastic Agents, Cell Differentiation, Humans, Neurons, Phenotype, Promoter Regions, Genetic, Protein Processing, Post-Translational, Proto-Oncogene Proteins, Stem Cells, Transcriptional Activation, Tumor Suppressor Protein p53, Apoptosis, Mice, Knockout, Gene Expression Regulation, Developmental, Ubiquitin, Ubiquitin-Protein Ligases, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.